Navigation Links
Treatment Eases Involuntary Laughing, Crying Tied to Alzheimer's, MS
Date:4/14/2010

Calming the condition can greatly improve patients' quality of life, experts note

WEDNESDAY, April 14 (HealthDay News) -- Involuntary crying or laughing can be a common symptom in patients with certain neurological disorders, such as Alzheimer's, multiple sclerosis or amyotrophic lateral sclerosis (ALS).

However, a combination of drugs could be the first effective long-term treatment for the problem, researchers say.

The new treatment for curbing these unwanted crying/laughing episodes -- known to doctors as "pseudobulbar affect" or PBA -- uses two drugs, dextromethorphan and low-dose quinidine.

Early indications are that the two drugs do reduce the incidence and severity of PBA episodes and improve quality of life.

"There's no FDA-approved therapy for pseudobulbar affect," noted study lead author Dr. Erik P. Pioro, director of the section for ALS and related disorders at the Cleveland Clinic in Ohio, and a member of the American Academy of Neurology (AAN). "The off-label medications that are being used have their own set of side effects and problems. So from a medical and patient care point of view, it would be very worthwhile to have an approved medication that is both safe and effective," he said.

Pioro presented the findings at a press conference held earlier this week at the AAN's annual meeting in Toronto.

The study authors note that PBA typically manifests in patients with an underlying neurological illness, including those with multiple sclerosis (MS), ALS (also known as Lou Gehrig's disease) or Alzheimer's, as well as patients suffering from other dementias and/or brain infections and injuries.

Pioro said that conservative estimates put the number of Americans with PBA at close to 2 million, although he said the figure might actually be as high as 6 million to 7 million.

Dextromethorphan is a common medication and a principle ingredient of standard cough syrup, according to Dr. Lily K. Jung, medical director of the neurology clinic and chief of neurology at the Swedish Medical Center in Seattle. The drug has previously been shown to have a "significant" effect upon parts of the brain responsible for behavioral control, she said at the press briefing.

Jung, who did not take part in the study, noted that quinidine is sometimes used to treat heart rhythm abnormalities. When combined at very low doses with dextromethorphan, it appears to help prolong that drug's usefulness.

In the study, Pioro and his colleagues enlisted 283 patients with PBA in an initial drug trial, during which some patients received one of two dosage levels of the two medications, while others received placebos.

After a two-week break, this was followed by a second phase involving 253 of the original study participants.

During the study's second part, patients were exposed to daily doses of the two-drug regimen for 12 weeks.

Pioro and his colleagues observed "significant improvement" among all the patients -- particularly among those who had not been exposed to the drug combo until the second part of the study.

Overall, Pioro noted that "there was an improvement of probably about 30 to 40 percent of symptoms" on average.

"Hopefully, we will soon have a very effective approved therapy to help these patients, which is important because this problem is probably much wider and more prevalent than we realize," he said.

"Very often patients who have this can be mistaken for having depression," Pioro explained. "But they're not depressed. Pseudobulbar affect is actually incongruent usually to the inner mood that the person has. So it can generate a lot of misconceptions. And patients will often be stigmatized, if you will, as a result."

Jung agreed. "This is exciting," she said, "because pseudobulbar affect can be so significantly socially disabling."

Still, further investigation into the drug combo's potential is warranted, since Pioro's study was relatively small. "Obviously more studies need to be done in larger groups of patients," Jung cautioned. "And testing for benefit should be done with other validated measures."

More information

There's more on motor neuron diseases (including pseudobulbar affect), at the U.S. National Institute of Neurological Disorders and Stroke.



SOURCES: Erik P. Pioro, M.D., Ph.D., director, section of ALS and related disorders, Cleveland Clinic, Cleveland, Ohio, and member American Academy of Neurology; Lily K. Jung, M.D., medical director, neurology clinic, and chief of neurology, Swedish Medical Center, Seattle; American Academy of Neurology meeting, Toronto, April 10-17, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Money Worries Delay Heart Attack Treatment
2. Sinus Dynamics Reaches Milestone with Treatment of Nasal Allergy, Sinus Infection, Acute and Chronic Sinusitis Treating 25,000th Patient
3. Southampton scientists begin Phase II patient trial for new asthma treatment
4. New study of autism reveals a DNA tag (methylation) amenable to treatment
5. Increase in Autism Rate and Treatments Focus of Autism Awareness Month
6. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
7. Qutenza Now Available for Treatment of Post-Shingles Pain
8. Drug Rehab Treatment Center Explains Rehabilitation Program Using YouTube
9. Childrens Hospital Bostons Pain Treatment Service is named Clinical Center of Excellence
10. Denver Plastic Surgeon Deploys Sophisticated Lasers in Modern Beauty, Anti-aging Treatments
11. Treatment resistance in some cancer cells may be reversible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... National recruitment firm ... life sciences executive with extensive sequencing and genomics experience, as Vice President of North ... Ms. Hill will be responsible for leading the sales team in the commercialization of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology: